Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Pancreas ; 51(5): 559-562, 2022 05 01.
Artículo en Inglés | MEDLINE | ID: mdl-35973017

RESUMEN

ABSTRACT: Neurofibromatosis type (NF-1) is an autosomal dominant disorder characterized predominantly by neurocutaneous manifestations. Involvement of the gastrointestinal tract is uncommon but is associated with a significant risk of malignancy. There are a handful of case reports linking NF-1 with pancreatic neuroendocrine tumors; these include gastrin-secreting variants with the attendant Zollinger-Ellison syndrome. We present the case of a 52-year-old lady who presented with recurrent peptic ulceration and diarrhea. Serum gastrin levels were elevated and magnetic resonance imaging demonstrated the presence of a pancreatic lesion with multiple liver metastases. The lesion was moderately fludeoxyglucose avid on positron emission tomography-computed tomography. Endoscopic ultrasonography-guided sampling revealed the presence of synaptophysin positive neuroendocrine cells with positive gastrin immunostaining. A conservative approach was adopted, and the patient's symptoms improved on proton pump inhibitors. Zollinger-Ellison syndrome is an important condition, which should be kept in mind in the patient with NF-1 who presents with recurrent peptic ulceration and diarrhea. The emerging association between these 2 conditions is being examined on a cellular and immunohistochemical level.


Asunto(s)
Gastrinoma , Tumores Neuroendocrinos , Neurofibromatosis 1 , Neoplasias Pancreáticas , Úlcera Péptica , Síndrome de Zollinger-Ellison , Diarrea , Femenino , Gastrinoma/complicaciones , Gastrinas , Humanos , Persona de Mediana Edad , Tumores Neuroendocrinos/complicaciones , Tumores Neuroendocrinos/genética , Neurofibromatosis 1/complicaciones , Neurofibromatosis 1/diagnóstico , Neurofibromatosis 1/genética , Neoplasias Pancreáticas/diagnóstico , Síndrome de Zollinger-Ellison/complicaciones , Síndrome de Zollinger-Ellison/diagnóstico , Síndrome de Zollinger-Ellison/patología
2.
Ann R Coll Surg Engl ; 91(8): 703-7, 2009 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-19909614

RESUMEN

INTRODUCTION: Hypotension is commonly associated with epidural use in postoperative patients and is usually treated with fluid or vasopressor therapy. The former can result in fluid overload, associated with significant morbidity. This study aimed to identify factors increasing the likelihood of fluid overload in elective patients. PATIENTS AND METHODS: A prospective audit of fluid therapy in elective, postoperative, epidural patients was carried out over a 6-week period in a teaching hospital in England. Demographic, biochemical, and fluid balance data were collected and analysed to determine which factors had the strongest correlation with fluid overload. Fluid overload was calculated as the percentage of net fluid input relative to pre-operative body weight (%FO). RESULTS: Thirty-two patients were included in this study. An overload of 10% of the patients' pre-operative body weight was considered significant. The mean fluid overload incurred by patients in this study was 8.17 l (range, 2.89-14.62 l); %FO was 11.32% (range, 3.67-26.10%). The strongest independently correlating factor to fluid overload was initial, postoperative plasma albumin. Patients with a plasma albumin less than 27 g/l developed significant overload: mean overload 9.75 l (range, 2.89-14.62 l), %FO 15.12% (range, 4.81-26.10%), whilst those with an albumin level greater than 27 g/l did not: mean overload 6.77 l (range, 3.34-11.48 l), %FO 7.96% (range, 3.67-13.93%); P = 0.0001. CONCLUSIONS: Patients receiving epidurals with initial, postoperative, plasma albumin levels below 27 g/l are at increased risk of significant fluid overload. Earlier instigation of vasopressor therapy in this subgroup of patients may help prevent this.


Asunto(s)
Analgesia Epidural/efectos adversos , Fluidoterapia/efectos adversos , Hipoalbuminemia/etiología , Albúmina Sérica/análisis , Peso Corporal , Femenino , Humanos , Hipotensión/etiología , Hipotensión/terapia , Masculino , Periodo Posoperatorio , Estudios Prospectivos , Factores de Riesgo , Vasoconstrictores/uso terapéutico , Equilibrio Hidroelectrolítico/fisiología
3.
Stroke ; 33(12): 2858-64, 2002 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-12468782

RESUMEN

BACKGROUND AND PURPOSE: Elevated levels of matrix metalloproteinases (MMPs), particularly MMP-1 and MMP-9, have been implicated in plaque rupture. It has been suggested that inhibition of MMPs may stabilize vulnerable atherosclerotic plaques and improve clinical outcome. The aim of the study was to investigate the ability of doxycycline, a nonspecific MMP inhibitor, to reduce MMP concentration in carotid atheroma. METHODS: The study design was a prospective, double-blind randomized trial. One hundred patients requiring carotid endarterectomy were randomized to receive 200 mg/d doxycycline or placebo for 2 to 8 weeks before surgery. During endarterectomy, carotid plaques were retrieved. The concentrations of MMPs and doxycycline were determined in the atherosclerotic tissue by enzyme-linked immunosorbent assay and high-performance liquid chromatography, respectively. Clinical events were recorded, as was the rate of preoperative embolization (transcranial Doppler). RESULTS: Analysis of endarterectomized specimens demonstrated a mean doxycycline concentration of 6.0 micro g/g wet weight in treated patients. Administration of doxycycline significantly reduced the concentration of MMP-1 in carotid plaques from a mean of 14.8 to 10.3 ng/100g wet weight (P=0.038). This difference was due to decreased MMP-1 transcript (P<0.001). There was no difference in any other MMP (MMP-2, -3, or -9) or tissue inhibitor of matrix metalloproteinases-1 or -2. CONCLUSIONS: Doxycycline penetrated atherosclerotic plaques with acceptable tissue levels. This resulted in a reduction in MMP-1 concentration because of decreased expression.


Asunto(s)
Enfermedades de las Arterias Carótidas/tratamiento farmacológico , Enfermedades de las Arterias Carótidas/enzimología , Doxiciclina/uso terapéutico , Inducción Enzimática/efectos de los fármacos , Metaloproteinasas de la Matriz/biosíntesis , Anciano , Arteriosclerosis/enzimología , Arteriosclerosis/patología , Enfermedades de las Arterias Carótidas/patología , Enfermedades de las Arterias Carótidas/cirugía , Método Doble Ciego , Doxiciclina/análisis , Endarterectomía Carotidea , Inhibidores Enzimáticos/análisis , Inhibidores Enzimáticos/uso terapéutico , Humanos , Inmunohistoquímica , Metaloproteinasa 1 de la Matriz/genética , Metaloproteinasa 1 de la Matriz/metabolismo , Metaloproteinasas de la Matriz/análisis , Metaloproteinasas de la Matriz/genética , Persona de Mediana Edad , Estudios Prospectivos , ARN Mensajero/análisis , ARN Mensajero/metabolismo , Inhibidor Tisular de Metaloproteinasa-1/análisis , Inhibidor Tisular de Metaloproteinasa-1/biosíntesis , Inhibidor Tisular de Metaloproteinasa-2/análisis , Inhibidor Tisular de Metaloproteinasa-2/biosíntesis
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA